US3980766A
(en)
|
1973-08-13 |
1976-09-14 |
West Laboratories, Inc. |
Orally administered drug composition for therapy in the treatment of narcotic drug addiction
|
DE2530563C2
(de)
|
1975-07-09 |
1986-07-24 |
Bayer Ag, 5090 Leverkusen |
Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
|
US4457933A
(en)
|
1980-01-24 |
1984-07-03 |
Bristol-Myers Company |
Prevention of analgesic abuse
|
US4684516A
(en)
|
1983-08-01 |
1987-08-04 |
Alra Laboratories, Inc. |
Sustained release tablets and method of making same
|
IT1188212B
(it)
|
1985-12-20 |
1988-01-07 |
Paolo Colombo |
Sistema per il rilascio a velocita' controllata di sostanze attive
|
US5236714A
(en)
|
1988-11-01 |
1993-08-17 |
Alza Corporation |
Abusable substance dosage form having reduced abuse potential
|
IT1237904B
(it)
|
1989-12-14 |
1993-06-18 |
Ubaldo Conte |
Compresse a rilascio a velocita' controllata delle sostanze attive
|
US5132142A
(en)
|
1991-03-19 |
1992-07-21 |
Glatt Gmbh |
Apparatus and method for producing pellets by layering power onto particles
|
US5654009A
(en)
|
1991-03-25 |
1997-08-05 |
Fujisawa Pharmaceutical Co., Ltd. |
Delayed action preparation
|
US5149538A
(en)
|
1991-06-14 |
1992-09-22 |
Warner-Lambert Company |
Misuse-resistive transdermal opioid dosage form
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5958459A
(en)
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5681585A
(en)
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US5478577A
(en)
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
IL110014A
(en)
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
GB9401894D0
(en)
|
1994-02-01 |
1994-03-30 |
Rhone Poulenc Rorer Ltd |
New compositions of matter
|
US6077533A
(en)
|
1994-05-25 |
2000-06-20 |
Purdue Pharma L.P. |
Powder-layered oral dosage forms
|
US7060293B1
(en)
|
1994-05-25 |
2006-06-13 |
Purdue Pharma |
Powder-layered oral dosage forms
|
US5411745A
(en)
|
1994-05-25 |
1995-05-02 |
Euro-Celtique, S.A. |
Powder-layered morphine sulfate formulations
|
US6491945B1
(en)
|
1994-09-16 |
2002-12-10 |
Alza Corporation |
Hydrocodone therapy
|
US5773031A
(en)
|
1996-02-27 |
1998-06-30 |
L. Perrigo Company |
Acetaminophen sustained-release formulation
|
AU2059297A
(en)
|
1996-03-12 |
1997-10-01 |
Alza Corporation |
Composition and dosage form comprising opioid antagonist
|
PT1014941E
(pt)
|
1996-06-26 |
2009-07-08 |
Univ Texas |
Formulação farmacêutica extrudível por termofusão
|
US6709678B2
(en)
|
1996-08-15 |
2004-03-23 |
Losan Pharma Gmbh |
Easy to swallow oral medicament composition
|
GB9619074D0
(en)
|
1996-09-12 |
1996-10-23 |
Smithkline Beecham Plc |
Composition
|
DE19651551C2
(de)
|
1996-12-11 |
2000-02-03 |
Klinge Co Chem Pharm Fab |
Opioidantagonisthaltige galenische Formulierung
|
JP3677156B2
(ja)
*
|
1997-09-05 |
2005-07-27 |
武田薬品工業株式会社 |
医薬
|
GB9721746D0
(en)
|
1997-10-15 |
1997-12-10 |
Panos Therapeutics Limited |
Compositions
|
US6066339A
(en)
|
1997-10-17 |
2000-05-23 |
Elan Corporation, Plc |
Oral morphine multiparticulate formulation
|
PL193273B1
(pl)
|
1997-12-22 |
2007-01-31 |
Euro Celtique Sa |
Postać dawkowania doustnego
|
PL341309A1
(en)
|
1997-12-22 |
2001-04-09 |
Euro Celtique |
Method of preventing overdosage of opioidic preparations
|
FR2772615B1
(fr)
|
1997-12-23 |
2002-06-14 |
Lipha |
Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
|
US6245357B1
(en)
|
1998-03-06 |
2001-06-12 |
Alza Corporation |
Extended release dosage form
|
US20060240105A1
(en)
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
PT1126826E
(pt)
|
1998-11-02 |
2008-11-25 |
Elan Pharma Int Ltd |
Composição de metilfenidato de libertação modificada multiparticulada
|
KR101476574B1
(ko)
|
1999-10-29 |
2014-12-24 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
IT1315274B1
(it)
|
1999-12-29 |
2003-02-03 |
Cip Ninety Two 92 Sa |
Composizioni farmaceutiche per la somministrazione localizzata nelcavo orale di farmaci antiinfiammatori non stereoidei utili per la
|
CN1423559A
(zh)
|
2000-02-08 |
2003-06-11 |
欧罗赛铁克股份有限公司 |
包含阿片样激动剂和拮抗剂的控释组合物
|
FR2811571B1
(fr)
|
2000-07-11 |
2002-10-11 |
Flamel Tech Sa |
Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
|
MXPA03003895A
(es)
*
|
2000-10-30 |
2003-07-28 |
Euro Celtique Sa |
Formulaciones de hidrocodona de liberacion controlada.
|
AU2141202A
(en)
|
2000-12-05 |
2002-06-18 |
Alexander Macgregor |
Hydrostatic delivery system for controlled delivery of agent
|
WO2002092059A1
(en)
|
2001-05-11 |
2002-11-21 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant opioid dosage form
|
US7125561B2
(en)
|
2001-05-22 |
2006-10-24 |
Euro-Celtique S.A. |
Compartmentalized dosage form
|
US20030064122A1
(en)
|
2001-05-23 |
2003-04-03 |
Endo Pharmaceuticals, Inc. |
Abuse resistant pharmaceutical composition containing capsaicin
|
WO2003002100A1
(en)
|
2001-06-26 |
2003-01-09 |
Farrell John J |
Tamper-proof narcotic delivery system
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
US7141250B2
(en)
|
2001-08-06 |
2006-11-28 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing bittering agent
|
EP1414418A1
(en)
*
|
2001-08-06 |
2004-05-06 |
Euro-Celtique S.A. |
Compositions and methods to prevent abuse of opioids
|
US7332182B2
(en)
|
2001-08-06 |
2008-02-19 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
|
US7144587B2
(en)
|
2001-08-06 |
2006-12-05 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
US7157103B2
(en)
|
2001-08-06 |
2007-01-02 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing irritant
|
US8900498B2
(en)
|
2001-10-12 |
2014-12-02 |
Monosol Rx, Llc |
Process for manufacturing a resulting multi-layer pharmaceutical film
|
US7790215B2
(en)
|
2002-03-26 |
2010-09-07 |
Purdue Pharma Lp |
Sustained-release gel coated compositions
|
US7300670B2
(en)
|
2002-04-03 |
2007-11-27 |
Unilab Pharmatech, Ltd. |
Oral suspension formulation
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
CA2491572C
(en)
|
2002-07-05 |
2010-03-23 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
DE10250084A1
(de)
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20040091528A1
(en)
|
2002-11-12 |
2004-05-13 |
Yamanouchi Pharma Technologies, Inc. |
Soluble drug extended release system
|
WO2004050066A1
(en)
|
2002-11-27 |
2004-06-17 |
The University Of Georgia Research Foundation, Inc. |
Microspheres and related processes and pharmaceutical compositions
|
EP1610767B1
(en)
|
2003-03-26 |
2011-01-19 |
Egalet A/S |
Morphine controlled release system
|
TWI357815B
(en)
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20090304793A1
(en)
|
2003-09-22 |
2009-12-10 |
Alpharma, Inc. |
Sustained release opioid formulations and methods of use
|
EP2298303A1
(en)
*
|
2003-09-25 |
2011-03-23 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
WO2005076697A2
(en)
|
2004-02-04 |
2005-08-25 |
Foamix Ltd. |
Cosmetic and pharmaceutical foam with solid matter
|
TWI350762B
(en)
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
DK1765292T3
(da)
|
2004-06-12 |
2018-01-02 |
Collegium Pharmaceutical Inc |
Misbrugs-forebyggende lægemiddelformuleringer
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
DE102004032103A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
US20060051298A1
(en)
*
|
2004-09-03 |
2006-03-09 |
Groenewoud Pieter J |
Abuse resistent pharmaceutical dosage and method of making same
|
FR2878161B1
(fr)
|
2004-11-23 |
2008-10-31 |
Flamel Technologies Sa |
Forme medicamenteuse orale, solide et concue pour eviter le mesusage
|
US20070231268A1
(en)
|
2004-11-24 |
2007-10-04 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US20080152595A1
(en)
|
2004-11-24 |
2008-06-26 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US20060177380A1
(en)
|
2004-11-24 |
2006-08-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US20060110327A1
(en)
|
2004-11-24 |
2006-05-25 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
FR2881652B1
(fr)
|
2005-02-08 |
2007-05-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale microparticulaire anti-mesuage
|
CA2610662A1
(en)
|
2005-05-09 |
2007-05-18 |
Foamix Ltd. |
Foamable vehicle and pharmaceutical compositions thereof
|
WO2006133733A1
(en)
|
2005-06-13 |
2006-12-21 |
Flamel Technologies |
Oral dosage form comprising an antimisuse system
|
WO2007048219A2
(en)
|
2005-09-09 |
2007-05-03 |
Labopharm Inc. |
Sustained drug release composition
|
PL116330U1
(en)
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
US8652529B2
(en)
|
2005-11-10 |
2014-02-18 |
Flamel Technologies |
Anti-misuse microparticulate oral pharmaceutical form
|
US20070184115A1
(en)
*
|
2005-12-30 |
2007-08-09 |
Biovail Laboratories International S.R.L. |
Modified release formulations of tramadol and uses thereof
|
US20070264346A1
(en)
*
|
2006-02-16 |
2007-11-15 |
Flamel Technologies |
Multimicroparticulate pharmaceutical forms for oral administration
|
WO2007096906A2
(en)
|
2006-02-27 |
2007-08-30 |
Panacea Biotec Ltd. |
Novel buccoadhesive compositions and process of preparation thereof
|
WO2007106550A2
(en)
|
2006-03-15 |
2007-09-20 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
WO2007107787A2
(en)
|
2006-03-20 |
2007-09-27 |
Karrar Ahmad Khan |
Liquid and solid dosage formulations containing date fruit (phoenix dactylifera)
|
CA2648280C
(en)
|
2006-04-03 |
2014-03-11 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
CA2648278C
(en)
|
2006-04-03 |
2019-05-28 |
Isa Odidi |
Drug delivery composition
|
US9023400B2
(en)
|
2006-05-24 |
2015-05-05 |
Flamel Technologies |
Prolonged-release multimicroparticulate oral pharmaceutical form
|
US8679540B2
(en)
|
2006-06-09 |
2014-03-25 |
Flamel Technologies |
Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
AU2007260821B2
(en)
|
2006-06-23 |
2012-06-21 |
Alkermes Pharma Ireland Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
KR20090023729A
(ko)
|
2006-06-23 |
2009-03-05 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 멜록시캄 및 조절 방출형 하이드로코돈을 포함하는 조성물
|
EP2032124A1
(en)
|
2006-06-27 |
2009-03-11 |
Biovail Laboratories International Srl |
Multiparticulate osmotic delivery system
|
WO2008021394A2
(en)
|
2006-08-15 |
2008-02-21 |
Theraquest Biosciences, Llc |
Pharmaceutical formulations of cannabinoids and method of use
|
WO2008024490A2
(en)
|
2006-08-24 |
2008-02-28 |
Theraquest Biosciences, Inc. |
Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
US8187636B2
(en)
*
|
2006-09-25 |
2012-05-29 |
Atlantic Pharmaceuticals, Inc. |
Dosage forms for tamper prone therapeutic agents
|
US20100143481A1
(en)
|
2006-11-08 |
2010-06-10 |
Dinesh Shenoy |
Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
|
WO2008122993A1
(en)
|
2007-04-09 |
2008-10-16 |
Panacea Biotec Limited |
Controlled release formulation of coated microparticles
|
NZ580972A
(en)
|
2007-06-04 |
2012-02-24 |
Egalet Ltd |
Controlled release pharmaceutical compositions for prolonged effect
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
US8110226B2
(en)
|
2007-07-20 |
2012-02-07 |
Mylan Pharmaceuticals Inc. |
Drug formulations having inert sealed cores
|
BRPI0821732A2
(pt)
|
2007-12-17 |
2015-06-16 |
Labopharm Inc |
Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
|
TWI454288B
(zh)
|
2008-01-25 |
2014-10-01 |
Gruenenthal Chemie |
藥物劑型
|
JP2011511782A
(ja)
|
2008-02-12 |
2011-04-14 |
アボット・ラボラトリーズ |
長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
|
EP2262367A4
(en)
|
2008-03-08 |
2011-04-20 |
Theraquest Biosciences Inc |
PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
|
TWI519322B
(zh)
|
2008-04-15 |
2016-02-01 |
愛戴爾製藥股份有限公司 |
包含弱鹼性藥物及控制釋放劑型之組合物
|
JP5214312B2
(ja)
*
|
2008-04-16 |
2013-06-19 |
ホソカワミクロン株式会社 |
固形製剤およびその製造方法
|
US20120208773A1
(en)
|
2008-08-12 |
2012-08-16 |
Valeant International (Barbados) Srl |
Pharmaceutical compositions with tetrabenazine
|
US20110053866A1
(en)
|
2008-08-12 |
2011-03-03 |
Biovail Laboratories International (Barbados) S.R.L. |
Pharmaceutical compositions
|
EP2367541B1
(en)
|
2008-12-16 |
2014-07-16 |
Paladin Labs Inc. |
Misuse preventative, controlled release formulation
|
NZ594208A
(en)
|
2009-02-06 |
2012-10-26 |
Egalet Ltd |
Pharmaceutical compositions resistant to abuse
|
EP2448406B1
(en)
|
2009-02-26 |
2016-04-20 |
Relmada Therapeutics, Inc. |
Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
|
MX2011011480A
(es)
*
|
2009-05-01 |
2012-02-28 |
Aptalis Pharmatech Inc |
Composicines de tabletas que se desintegran oralmente que comprenden combinaciones de analgesicos no opioides y opioides.
|
MX2012003082A
(es)
|
2009-09-17 |
2012-04-19 |
Cadila Healthcare Ltd |
Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
|
ES2569925T3
(es)
|
2009-09-30 |
2016-05-13 |
Acura Pharmaceuticals, Inc. |
Métodos y composiciones de disuasión del abuso
|
CA2784407A1
(en)
|
2009-12-17 |
2011-07-14 |
Cima Labs Inc. |
Abuse-resistant formulations
|
US20130022646A1
(en)
|
2010-02-09 |
2013-01-24 |
Rudnic Edward M |
Controlled Release Formulations of Opioids
|
US20120321674A1
(en)
|
2011-02-17 |
2012-12-20 |
Michael Vachon |
Technology for Preventing Abuse of Solid Dosage Forms
|
EP2538928B1
(en)
|
2010-02-24 |
2017-05-03 |
Cima Labs Inc. |
Abuse-resistant formulations
|
FR2959130A1
(fr)
|
2010-04-21 |
2011-10-28 |
Sanofi Aventis |
Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
|
FR2960775A1
(fr)
|
2010-06-07 |
2011-12-09 |
Ethypharm Sa |
Microgranules resistants au detournement
|
US8861890B2
(en)
|
2010-11-24 |
2014-10-14 |
Douglas Alan Lefler |
System and method for assembling and displaying individual images as a continuous image
|
WO2012112952A1
(en)
|
2011-02-17 |
2012-08-23 |
QRxPharma Ltd. |
Technology for preventing abuse of solid dosage forms
|
AU2012235878B2
(en)
|
2011-03-25 |
2015-10-15 |
Purdue Pharma L.P. |
Controlled release pharmaceutical dosage forms
|
WO2013003622A1
(en)
|
2011-06-28 |
2013-01-03 |
Neos Therapeutics, Lp |
Dosage forms for oral administration and methods of treatment using the same
|
AR087360A1
(es)
*
|
2011-07-29 |
2014-03-19 |
Gruenenthal Gmbh |
Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
|
US9065156B2
(en)
|
2011-08-08 |
2015-06-23 |
Wisconsin Alumni Research Foundation |
Photovoltaic capacitor for direct solar energy conversion and storage
|
EP2755638B1
(en)
|
2011-09-16 |
2016-06-01 |
Purdue Pharma LP |
Tamper resistant immediate release formulations
|
JP6110384B2
(ja)
|
2011-09-16 |
2017-04-05 |
パーデュー ファーマ エルピー |
不正改変抵抗性医薬製剤
|
ES2603278T3
(es)
*
|
2011-12-09 |
2017-02-24 |
Purdue Pharma Lp |
Formas farmacéuticas de dosificación que comprenden poli (epsilon-caprolactona) y óxido de polietileno
|
CN104144681A
(zh)
|
2012-03-02 |
2014-11-12 |
罗德兹制药股份有限公司 |
抗破坏性立即释放型制剂类
|
CA2877183A1
(en)
*
|
2012-07-06 |
2014-01-09 |
Egalet Ltd. |
Abuse deterrent pharmaceutical compositions for controlled release
|
US10322120B2
(en)
|
2012-07-31 |
2019-06-18 |
Persion Pharmaceuticals Llc |
Treating pain in patients with hepatic impairment
|
EP2906202A4
(en)
|
2012-10-15 |
2016-04-27 |
Isa Odidi |
DRUG FORMULATIONS FOR ORAL ADMINISTRATION
|
US9132096B1
(en)
*
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|